EP1696903A1 - Association de 2,3-dibenzylbutyrolactone et de licochalcone-a - Google Patents

Association de 2,3-dibenzylbutyrolactone et de licochalcone-a

Info

Publication number
EP1696903A1
EP1696903A1 EP04819609A EP04819609A EP1696903A1 EP 1696903 A1 EP1696903 A1 EP 1696903A1 EP 04819609 A EP04819609 A EP 04819609A EP 04819609 A EP04819609 A EP 04819609A EP 1696903 A1 EP1696903 A1 EP 1696903A1
Authority
EP
European Patent Office
Prior art keywords
skin
preparations
polyethylene glycol
weight
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP04819609A
Other languages
German (de)
English (en)
Inventor
Stefan Gallinat
Ludger Kolbe
Christopher Mummert
Rainer Wolber
Franz STÄB
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Beiersdorf AG
Original Assignee
Beiersdorf AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beiersdorf AG filed Critical Beiersdorf AG
Publication of EP1696903A1 publication Critical patent/EP1696903A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/121—Ketones acyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A61K36/484—Glycyrrhiza (licorice)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/35—Ketones, e.g. benzophenone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4973—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9783—Angiosperms [Magnoliophyta]
    • A61K8/9789—Magnoliopsida [dicotyledons]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/18—Antioxidants, e.g. antiradicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
    • A61Q17/04—Topical preparations for affording protection against sunlight or other radiation; Topical sun tanning preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/004—Aftersun preparations

Definitions

  • the present invention relates to cosmetic or dermatological preparations containing active ingredients for the care and protection of the skin, in particular sensitive skin, and very particularly in the foreground of skin aged or aging due to intrinsic and / or extrinsic factors, and the use of such active ingredients and combinations of such active ingredients in the field of cosmetic and dermatological skin care.
  • Cosmetic skin care is primarily to be understood as meaning that the natural function of the skin as a barrier against environmental influences (eg dirt, chemicals, microorganisms) and against the loss of the body's own substances (eg water, natural fats, electrolytes) is strengthened or restored ,
  • the barrier effect of the skin can be quantified by determining the transepidermal water loss (TEWL - transepidermal water loss). This is the evaporation of water from the inside of the body without taking into account the loss of water when sweating.
  • the determination of the TEWL value has proven to be extremely informative and can be used to diagnose cracked or chapped skin, to determine the compatibility of chemically differently structured surfactants and the like.
  • the water content in the uppermost skin layer is of the greatest importance for the beauty and care of the skin. It can be influenced to a limited extent by introducing moisture regulators.
  • Anionic surfactants which are generally components of cleaning preparations, can increase the pH value in the horny layer for a long time, which greatly hinders regenerative processes that serve to restore and renew the skin's barrier function. In this case, a new, often very unfavorable equilibrium occurs in the horny layer between regeneration and the loss of essential substances through regular extraction, which significantly affects the external appearance of the skin and the physiological functioning of the horny layer.
  • the changes in the lipid pattern of the very dry, non-eczematous skin of patients with atopic eczema represent an extreme case for the deviations that are found in the dry skin of healthy people.
  • ceramides which are greatly reduced in their quantity and are also composed differently.
  • the deficit in ceramides 1 and 3 is particularly striking, it being known in particular for ceramide 1 that it increases the order of the lipids in the intercellular membrane systems in a special way.
  • Adverse changes in the lipid membranes of the type described above may be due to miscontrolled lipid biosynthesis and also ultimately increase transepidermal water loss. Long-lasting barrier weakness, in turn, makes healthy skin more sensitive and in individual cases can contribute to the development of eczematous processes in the diseased skin.
  • the effect of ointments and creams on the barrier function and hydration of the horny layer usually does not consist in restoring or strengthening the physicochemical properties of the lamellae made of intercellular lipids.
  • a major partial effect is due to the mere covering of the treated skin areas and the resulting water retention in the underlying horny layer.
  • Co-applied hygroscopic Substances bind the water so that there is a measurable increase in the water content in the horny layer.
  • this purely physical barrier can be removed relatively easily.
  • the skin care effect can diminish with regular treatment, so that the status quo is finally reached again even during treatment.
  • the condition of the skin may temporarily worsen after discontinuation.
  • a sustainable product effect is not achieved or only to a limited extent.
  • the aim of the present invention was therefore to find ways to avoid the disadvantages of the prior art.
  • the effects of skin care products should be physiological, quick and sustainable.
  • Skin care in the sense of the present invention is to be understood primarily as meaning that the natural function of the skin acts as a barrier against environmental influences (e.g. dirt, chemicals, microorganisms) and against the loss of the body's own substances (e.g. water, lipids) , Electrolytes) is strengthened or restored.
  • environmental influences e.g. dirt, chemicals, microorganisms
  • the loss of the body's own substances e.g. water, lipids
  • Electrolytes e.g. water, lipids
  • the effect of ointments and creams on the barrier function and the hydration of the horny layer is based essentially on the covering (occlusion) of the treated skin areas.
  • the ointment or cream is, so to speak, a (second) artificial barrier that is supposed to prevent water loss from the skin.
  • This physical barrier can be easily for example with cleaning agents - are removed again, whereby the original, impaired state is reached again.
  • the skin care effect can decrease with regular treatment. After stopping the application of the product, the skin quickly returns to the state before the start of treatment. With certain products, the condition of the skin may even temporarily deteriorate. As a rule, a sustainable product effect is not achieved or only to a limited extent.
  • the effect of nourishing cleansing products is essentially an efficient regreasing with sebum lipid-like substances.
  • the damage to the homolayer barrier can be further limited.
  • the prior art lacks preparations which have a positive effect on the barrier function and hydration of the horny layer and which strengthen or even restore the physicochemical properties of the horny layer and in particular of the lamellae from intercellular lipids.
  • the object of the present invention was therefore to eliminate the disadvantages of the prior art.
  • skin-care preparations and preparations for cleaning the skin should be made available which maintain or restore the skin's barrier properties, especially when the natural regeneration of the skin is not sufficient. They should also be suitable for the treatment and prophylaxis of consequential damage to skin drying out, for example fissures or inflammatory or allergic processes or also neurodermatitis.
  • the effect of the preparations should be physiological, quick and sustainable.
  • the invention relates to preparations with extremely low so-called "stinging potential".
  • Typical reactions of "stinging" to sensitive skin are reddening, tension and burning of the skin as well as itching.
  • Cutting 'phenomena can be regarded as disorders to be treated cosmetically.
  • severe itching particularly severe itching in the case of atopy, can also be described as a more serious dermatological disorder.
  • Typical disturbing neurosensory phenomena associated with the terms "stinging” or “sensitive skin” are reddening of the skin, tingling, tingling, tension and burning of the skin and itching.
  • PJFrosch and AMKligman describe a method for estimating the "stinging potential" of topically administered substances.
  • Lactic acid and pyruvic acid for example, are used here as positive substances.
  • amino acids, in particular glycine were also found to be neurosensory active (such substances are called “Stinger”). According to previous knowledge, such a sensitivity to very specific substances occurs individually in different ways. This means that a person who experiences “stinging effects" when in contact with a substance is very likely to experience it repeatedly with each subsequent contact. Contact with other "Stingers" can just as easily be without any reaction.
  • Sensitive skin affects a growing number of adults and children. Sensitive skin is a combination of various symptoms, such as hyper-reactive and intolerant skin. But atopic skin can also be summed up. These skin conditions are often affected by those affected, not entirely correct, referred to as "allergic" skin. Although an allergic disease can lead to symptoms of sensitive skin, the appearance of "sensitive skin” is not limited to allergy sufferers
  • Erythematous skin symptoms also appear as a side effect with certain skin diseases or irregularities. For example, the typical rash in the appearance of acne is usually more or less reddened.
  • active substances and preparations containing such active substances should be made available for the cosmetic and dermatological treatment and / or prophylaxis of erythematous, inflammatory, allergic or autoimmune-reactive symptoms, in particular dermatoses, but also the appearance of the "stinging".
  • active substances or preparations containing such active substances should be made available which can be used for immune stimulation of the skin, advantageously also for immune stimulation in the sense of the effect promoting wound healing.
  • the present invention relates to cosmetic and dermatological preparations for the prophylaxis and treatment of cosmetic or dermatological skin changes such as, for example, the undesired pigmentation, for example local hyper- and deficient pigmentations (for example liver spots, freckles), but also for purely cosmetic lightening of larger, the individual skin type of adequately pigmented skin areas.
  • Melanocytes are responsible for the pigmentation of the skin. They can be found in the bottom layer of the epidermis, the stratum basale, next to the basal cells as - depending on the skin type, either isolated or more or less frequently occurring pigment-forming cells.
  • melanocytes contain melanosomes which, when stimulated by UV radiation, form increased melanin. This is transported into the keratinocyte and causes a more or less pronounced brown or brown skin color.
  • Melanin is formed as the final stage of an oxidative process in which tyrosine with the help of the enzyme tyrosinase via 3,4-dihydroxyphenylalanine (dopa), dopa-quinone, leucodopachrome, dopachrome, 5,6-dihydroxyindole and indole-5,6-quinone finally in Melanin is converted.
  • UV radiation e.g. freckles, ephe- lides
  • genetic disposition e.g. incorrect pigmentation of the skin during wound healing or scarring or skin aging (e.g. Lentigines seniles).
  • the object of the present invention was also to remedy these shortcomings.
  • the aim of skin care is also to compensate for the loss of fat and water in the skin caused by daily washing. This is especially important when the natural regeneration ability is insufficient.
  • skin care products are intended to protect against environmental influences, especially sun and wind, and to delay skin aging.
  • Chronological skin aging is caused, for example, by endogenous, genetically determined factors. The following structural damage and functional disorders occur in the epidermis and dermis due to aging, which can also fall under the term "senile xerosis":
  • Exogenous factors such as UV light and chemical pollutants can be cumulative and e.g. accelerate or complement the endogenous aging processes.
  • exogenous factors e.g. the following structural damage and functional disorders in the skin that go beyond the extent and quality of the damage with chronological aging:
  • the present invention relates in particular to products for the care of naturally aged skin and for the treatment of the consequential damage caused by light aging, in particular the phenomena listed under a) to g).
  • Products for the care of aged skin are known per se. They contain e.g. Retinoids (vitamin A acid and / or its derivatives) or vitamin A and / or its derivatives.
  • Retinoids vitamin A acid and / or its derivatives
  • their effect on structural damage is limited in scope.
  • the use of products containing vitamin A acid often causes severe erythematous skin irritation. Retinoids can therefore only be used in low concentrations.
  • the present invention relates to cosmetic preparations with effective protection against harmful oxidation processes in the skin, but also for protection cosmetic preparations themselves or to protect the components of cosmetic preparations from harmful oxidation processes.
  • the present invention further relates to antioxidants, preferably those which are used in skin-care cosmetic or dermatological preparations.
  • the invention also relates to cosmetic and dermatological preparations containing such antioxidants.
  • the present invention relates to cosmetic and dermatological preparations for the prophylaxis and treatment of cosmetic or dermatological skin changes such as e.g. skin aging, especially skin aging caused by oxidative processes.
  • the present invention further relates to active substances and preparations containing such active substances for cosmetic and dermatological treatment or prophylaxis of erythematous, inflammatory, allergic or autoimmune-reactive symptoms, in particular dermatoses.
  • the present invention relates to active substance combinations and preparations which are used for the prophylaxis and treatment of light-sensitive skin, in particular photodermatoses.
  • UVC range rays with a wavelength shorter than 290 nm
  • UVB range rays in the range between 290 nm and 320 nm, the so-called UVB range, cause an erythema simple sunburn or even more or less severe burns.
  • the narrower range around 308 nm is given as a maximum of the erythema effectiveness of sunlight.
  • UVB radiation which are derivatives of 3-benzylidene camphor, 4-aminobenzoic acid, cinnamic acid, salicylic acid, benzophenone and also 2-phenylbenzimidazole. It is also important to have filter substances available for the range between about 320 nm and about 400 nm, the so-called UVA range, since their rays can cause reactions in light-sensitive skin. It has been proven that UVA radiation damages the elastic and collagen fibers of the connective tissue, which causes the skin to age prematurely, and that it can be seen as the cause of numerous phototoxic and photoallergic reactions. The damaging influence of UVB radiation can be intensified by UVA radiation.
  • UV radiation can also lead to photochemical reactions, in which case the photochemical reaction products interfere with the skin's metabolism.
  • Such photochemical reaction products are predominantly free radical compounds, for example hydroxyl radicals, singlet oxygen.
  • Undefined radical photo products which are created in the skin itself, can also display uncontrolled subsequent reactions due to their high reactivity.
  • singlet oxygen a non-radical excited state of the oxygen molecule can occur with UV radiation, just as short-lived epoxies and many others.
  • Singlet oxygen for example, is characterized by increased reactivity compared to the triplet oxygen (radical ground state) that is normally present. However, there are also excited, reactive (radical) triplet states of the oxygen molecule.
  • UV radiation also belongs to ionizing radiation. There is therefore a risk that ionic species also develop when exposed to UV, which in turn can then oxidatively intervene in the biochemical processes.
  • antioxidants and / or free radical scavengers can be incorporated into the cosmetic or dermatological formulations.
  • vitamin E a substance with a known antioxidant effect, in light protection formulations, but the efficacy achieved here still remains. kung far behind the hoped for.
  • the object of the invention was therefore also to provide cosmetic, dermatological and pharmaceutical active substances and preparations and light protection formulations which are used for the prophylaxis and treatment of light-sensitive skin, in particular photodermatoses, preferably PLD.
  • Antioxidants are mainly used as protective substances against the spoilage of the preparations containing them. Nevertheless, it is known that undesirable oxidation processes can also occur in human and animal skin. Such processes play an essential role in skin aging.
  • antioxidants and / or free radical scavengers can be incorporated into cosmetic or dermatological formulations.
  • antioxidants and radical scavengers are known. It has already been proposed in US Pat. Nos. 4,144,325 and 4,248,861 and from numerous other documents to use vitamin E, a substance with a known antioxidant effect in sunscreen formulations, but the effect achieved here also falls far short of the hoped-for effect.
  • the object of the present invention was therefore to find ways which avoid the disadvantages of the prior art.
  • the effect of repairing the damage associated with endogenous, chronological and exogenous skin aging and the Prophylaxis to be permanent, sustainable and without the risk of side effects.
  • active ingredient combinations according to the invention or cosmetic or topical dermatological preparations with an effective content of active ingredient combinations according to the invention surprisingly offers effective treatment, but also prophylaxis of deficient, sensitive or hypoactive skin conditions or deficit, sensitive or hypoactive conditions of skin appendages of signs of premature aging the skin (eg wrinkles, age spots, telangiectasia) and / or the appendages of the skin, of environmental ones (smoking, smog, reactive oxygen species, free radicals) and in particular light-related negative changes in the skin and appendages, of light-related skin damage - t from pigmentation disorders, from sensitive, irritated and itchy skin, from dry skin conditions and barrier layer disorders, from hair loss and for improved hair growth - from inflammatory skin conditions as well as atopic eczema, seborrheic eczema, polymorphic light dermatosis, psoriasis, vitiligo
  • the active ingredient according to the invention or cosmetic or topical dermatological preparations with an effective content of the active ingredient according to the invention also surprisingly serves to calm sensitive or irritated skin to stimulate collagen, hyaluronic acid, elastin synthesis to stimulate ceramide synthesis of the skin - to stimulate the skin intracellular DNA synthesis, especially for deficient or hypoactive skin conditions.
  • to increase cell renewal and regeneration of the skin to increase the skin's own protection and repair mechanisms (e.g. for dysfunctional enzymes, DNA, lipids, proteins) - for pre-treatment and post-treatment with topical application of laser and abrasive treatments, e.g. B. serve the reduction of skin folds and scars to counteract the resulting skin irritation and to promote the regeneration processes in the injured skin.
  • the 2,3-dibenzylbutyrolactone derivatives and licochalcone A are preferably present in the active compound combinations according to the invention in ratios of 50: 1 to 1:50, preferably 10: 1 to 1:10, particularly preferably 2: 1 to 1: 2.
  • the 2,3-dibenzylbutyrolactone derivatives according to the invention and / or their glycosides are derived from the 2,3-dibenzylbutyrolactone also according to the invention, which is characterized by the following structure:
  • 2,3-dibenzylbutyrolactone, 2,3-dibenzylbutyrolactone derivatives and / or their glycosides in all their stereoisomeric forms which can be present both as a racemate and in enantiomerically pure form, and also in racemic mixtures with different enantiomeric proportions.
  • the formulation comprises 2,3-dibenzylbutyrolactone derivatives and / or their glycosides also the 2,3-dibenzylbutyrolactone.
  • the 2,3-dibenzylbutyrolactone derivatives according to the invention and / or their glycosides can advantageously be added to the preparation according to the invention in the form of plant extracts.
  • Aqueous-alcoholic extracts from plants have proven particularly useful.
  • extracts and distillates obtained with other forms of extraction and methods for example extracts obtained with carbon dioxide as extracting agent and steam distillates, can also be advantageously formulated into the preparations according to the invention.
  • Arctiin, arctigenin, Prestegan B, matairesinol, tracheloside and / or trachelogenin are used as 2,3-dibenzylbutyrolactone derivatives preferred according to the invention and / or their glycosides.
  • the derivatives with the following stereochemical structure are particularly preferred:
  • Arctiin and prestegan B are very particularly preferred according to the invention.
  • the 2,3-dibenzylbutyrolactone derivatives and / or their glycosides according to the invention can be easily incorporated into conventional cosmetic and / or dermatological preparations, such as sunscreen preparations, skin care preparations, anti-wrinkle preparations, but also other preparations, for example pharmaceutical preparations.
  • Preparations according to the invention advantageously contain 0.01-25% by weight of one or more 2,3-dibenzylbutyrolactone derivatives, preferably 0.1-20% by weight, in particular 1-10% by weight, in each case based on the total weight of the preparations.
  • the plant species Glycyrrhiza inflata like the licorice Glycyrrhiza glabra, which belongs to Europe, belongs to the genus Glycyrrhiza, which belongs to the Fabaceae (pea family) plant family.
  • the drug Radix Glycyrrhizae inflatae i.e. the root of the plant, is used, for example, in Far Eastern medicine. The use of the drug as an anti-inflammatory is also known.
  • a component of the aqueous extract from Radix Glycyrrhizae inflatae is the licochalcon
  • the preparations contain 0.0001 to 5% by weight, in particular 0.001 to 1% by weight, very particularly 0.005 to 0.15% by weight of licochalcone A, based on the total weight of the preparation. It is also advantageous according to the invention in particular if the preparations contain 0.001 to 10% by weight, in particular 0.05 to 5% by weight, very particularly 0.01 to 2% by weight, of one or more polyols, based on the total weight of the Preparation.
  • the preparations contain licocalchon as a constituent of plant extracts, in particular of Radix Glycyrrhizae inflatae.
  • licochalcone is in the form of an aqueous extract in which - licochalcone A water, if appropriate, one or more polyols are present.
  • the cosmetic or dermatological preparations 0.001 to 10% by weight, in particular 0.05 to 5% by weight, very particularly 0.01 to 2% by weight, of an aqueous extract from Radix Glycyrrhizae inflatae included, based on the total weight of the preparation.
  • the cosmetic or dermatological preparations contain 0.001 to 10% by weight, in particular 0.05 to 5% by weight, very particularly 0.01 to 2% by weight, of one or more polyols, based on the total weight of the preparation.
  • Licochalcone A in other vehicle systems in a concentration of 0.0001 to 5% by weight, in particular 0.001 to 1% by weight, very particularly 0.005-0.05% by weight. Accordingly, the use of active substance combinations according to the invention for the prophylaxis and treatment of inflammatory skin conditions - including atopic eczema - and / or for skin protection in the case of sensitive, determined dry skin is accordingly also according to the invention.
  • Cosmetic or dermatological preparations according to the invention preferably contain 0.001-1.0% by weight, particularly preferably 0.01-1% by weight, of active compound combinations according to the invention, based on the total composition of the preparations.
  • antioxidants are advantageously selected from the group consisting of amino acids (eg glycine, histidine, tyrosine, tryptophan) and their derivatives, imidazoles (eg urocanic acid) and their derivatives, peptides such as D, L-carnosine, D-carnosine, L- Carnosine and its derivatives (eg anserine), carotenoids, carotenes (eg ⁇ -carotene, ⁇ -carotene, lycopene) and their derivatives, chlorogenic acid and their derivatives, lipoic acid and their derivatives (eg dihydrolipoic acid), aurothioglucose, propylthiouracil and other thiols (eg thioredoxin, glutathione, cysteine, cystine, cystamine and their glycosyl, N-acetyl, methyl,
  • amino acids eg glycine, histidine, tyrosine, tryptophan
  • buthioninsulfoxinsulfoximine, homocystone, homocystone pent ⁇ -, hexa-, heptathioninsulfoximine) in very low tolerable doses e.g. pmol to ⁇ mol / kg
  • metal chelators e.g. ⁇ -hydroxy fatty acids, palmitic acid, phytic acid, lactoferrin), ⁇ -hydroxy acids (e.g. citric acid, Lactic acid, malic acid), humic acid, bile acid, bile extracts, bilirubin, biliverdin, EDTA, EGTA and their derivatives, unsaturated fatty acids and their derivatives (e.g.
  • ⁇ -linolenic acid linoleic acid, oleic acid
  • folic acid and its derivatives Ubiquinone and ubiquinol and their derivatives
  • vitamin C and derivatives e.g. ascorbyl palmitate, Mg ascorbyl phosphate, ascorbyl acetate
  • tocopherols and derivatives e.g.
  • vitamin E acetate
  • vitamin A and derivatives vitamin A palmitate
  • coniferyl benzoate Benzoin, rutinic acid and its derivatives, ⁇ -glycosyl rutin, ferulic acid, furfurylidene glucitol, carnosine, butylated hydroxytoluene, butylated hydroxyanisole, nordihydroguajak resin acid, nordihydroguajaretic acid, trihydroxybutyrophenone, uric acid and its derivative e, mannose and its derivatives, zinc and its derivatives (for example ZnO, ZnS0 4 ) selenium and its derivatives (for example selenium methionine), stilbenes and their derivatives (for example stilbene oxide, trans-stilbene oxide) and which are suitable according to the invention Derivatives (salts, esters, ethers, sugars, nucleotides, nucleosides, peptides and lipids) of these active ingredients.
  • the amount of the antioxidants (one or more compounds) in the preparations is preferably 0.001 to 30% by weight, particularly preferably 0.05-20% by weight, in particular 1-10% by weight, based on the total weight the preparation.
  • the prophylaxis or the cosmetic or dermatological treatment with the active ingredient used according to the invention or with the cosmetic or topical dermatological Tological preparations with an effective content of active ingredient used according to the invention are carried out in the usual way, in such a way that the active ingredient used according to the invention or the cosmetic or topical dermatological preparations with an effective content of active ingredient used according to the invention is applied to the affected skin areas.
  • the active ingredient used according to the invention can advantageously be incorporated into customary cosmetic and dermatological preparations, which can be in various forms. So you can e.g. a solution, an emulsion of the type water-in-oil (W / O) or of the type oil-in-water (O / W), or a multiple emulsions, for example of the type water-in-oil-in-water (W / O / W) or oil-in-water-in-oil (O / W / O), a hydrodispersion or lipodispersion, a gel, a solid stick or an aerosol.
  • Emulsions according to the invention in the sense of the present invention are advantageous and contain e.g. Fats, oils, waxes and / or other fat bodies, as well as water and one or more emulsifiers, as are usually used for such a type of formulation.
  • the active ingredient used according to the invention into aqueous systems or surfactant preparations for cleaning the skin and hair.
  • the cosmetic preparations according to the invention can therefore contain cosmetic auxiliaries as are usually used in such preparations, e.g. Preservatives, bactericides, deodorising substances, antiperspirants, insect repellents, vitamins, anti-foaming agents, dyes, pigments with a coloring effect, thickeners, softening substances, moisturizing and / or moisturizing substances, fats, oils, waxes or other common components a cosmetic formulation such as alcohols, polyols, polymers, foam stabilizers, electrolytes, organic solvents or silicone derivatives.
  • cosmetic auxiliaries as are usually used in such preparations, e.g. Preservatives, bactericides, deodorising substances, antiperspirants, insect repellents, vitamins, anti-foaming agents, dyes, pigments with a coloring effect, thickeners, softening substances, moisturizing and / or moisturizing substances, fats, oils, waxes or other common components a cosmetic formulation such as alcohols, polyols
  • Medical topical compositions within the meaning of the present invention generally contain one or more medicaments in an effective concentration.
  • Preparations according to the invention can also advantageously contain substances which absorb UV radiation in the UVB range, the total amount of filter substances e.g. 0.1% by weight to 30% by weight, preferably 0.5 to 10% by weight. is in particular 1.0 to 6.0% by weight, based on the total weight of the preparations, in order to provide cosmetic preparations which protect the hair or the skin from the entire range of ultraviolet radiation. They can also serve as a sunscreen for the hair.
  • the total amount of filter substances e.g. 0.1% by weight to 30% by weight, preferably 0.5 to 10% by weight. is in particular 1.0 to 6.0% by weight, based on the total weight of the preparations, in order to provide cosmetic preparations which protect the hair or the skin from the entire range of ultraviolet radiation. They can also serve as a sunscreen for the hair.
  • Oil-soluble UVB filters which are advantageous according to the invention are, for example: 3-benzylidene camphor derivatives, preferably 3- (4-methylbenzylidene) camphor, 3-benzylidene camphor; 4-aminobenzoic acid derivatives, preferably 4- (dimethylamino) benzoic acid (2-ethyl-hexyl) ester, 4- (dimethylamino) benzoic acid amyl ester; Esters of cinnamic acid, preferably 4-methoxycinnamic acid (2-ethylhexyl) ester, 4-methoxycinnamic acid isopentyl ester; Esters of salicylic acid, preferably salicylic acid (2-ethylhexyl) ester, salicylic acid (4-isopropylbenzyl) ester, salicylic acid homomethyl ester, derivatives of benzophenone
  • Examples of advantageous water-soluble UVB filters are: Salts of 2-phenylbenzimidazole-5-sulfonic acid such as its sodium, potassium or triethanolammonium salt, and also the sulfonic acid itself; Sulfonic acid derivatives of benzophenones, preferably 2-hydroxy-4-methoxybenzophenone-5-sulfonic acid and its salts; Sulfonic acid derivatives of 3-benzylidene camphor, such as 4- (2-oxo-3-bomylidene-methyl) benzenesulfonic acid, 2-methyl-5- (2-oxo-3-bomylidene-methyl) sulfonic acid and their salts and 1,4- di (2-oxo-10-sulfo-3-bornylidenemethyl) -benzene and its salts (the corresponding 10-sulfato compounds, for example the corresponding sodium, potassium or triethanolammonium salt), also as benzene-1 , 4-di (2-oxo-3-bornyliden
  • UVB filters which can be used in combination with the active compound combinations according to the invention, is of course not intended to be limiting.
  • UVA filters that are usually contained in cosmetic preparations.
  • These substances are preferably derivatives of dibenzoylmethane, in particular 1- (4'-tert-butylphenyl) -3- (4'-methoxyphenyl) propane-1, 3-dione and 1-phenyl-3 - (4'-Isopropylphenyl) propane-1,3-dione.
  • the quantities used for the UVB combination can be used.
  • Cosmetic and dermatological preparations according to the invention advantageously also contain inorganic pigments based on metal oxides and / or other metal compounds which are sparingly soluble or insoluble in water, in particular the oxides of titanium (Ti0 2 ), zinc (ZnO), iron (eg Fe 2 0 3 ), zirconium (Zr0 2 ), silicon (Si0 2 ), manganese (eg MnO), aluminum (Al 2 0 3 ), cerium (eg Ce 2 0 3 ), mixed oxides of the corresponding metals and mixtures of such oxides. It is particularly preferably pigments based on TiO 2 .
  • the inorganic pigments are in hydrophobic form, ie that they have been treated to be water-repellent on the surface.
  • This surface treatment can consist in that the pigments are provided with a thin hydrophobic layer by methods known per se. Such a method consists, for example, in that the hydrophobic surface layer according to a direction
  • n and m are stoichiometric parameters to be used at will, R and R 'are the desired organic radicals.
  • hydrophobized pigments shown in analogy to DE-OS 33 14 742 are advantageous.
  • Advantageous Ti0 2 pigments are available, for example, under the trade names MT 100 T from TAYCA, M 160 from Kemira and T 805 from Degussa.
  • Preparations according to the invention can also contain anionic, nonionic and / or amphoteric surfactants, especially if crystalline or microcrystalline solids, for example inorganic micropigments, are to be incorporated into the preparations according to the invention.
  • Surfactants are amphiphilic substances that can dissolve organic, non-polar substances in water.
  • hydrophilic parts of a surfactant molecule are mostly polar functional groups, for example -COO " , -OS0 3 2" , -S0 3 " , while the hydrophobic parts generally represent non-polar hydrocarbon residues.
  • Surfactants are generally of type and charge of the hydrophilic part of the molecule. Four groups can be distinguished here:
  • Anionic surfactants generally have carboxylate, sulfate or sulfonate groups as functional groups. In aqueous solution they form negatively charged organic ions in an acidic or neutral environment. Cationic surfactants are almost exclusively due to that Labeled presence of a quaternary ammonium group. In aqueous solution, they form positively charged organic ions in an acid or neutral environment. Amphoteric surfactants contain both anionic and cationic groups and accordingly behave in aqueous solution like anionic or cationic surfactants depending on the pH. They have a positive charge in a strongly acidic environment and a negative charge in an alkaline environment. In the neutral pH range, however, they are zwitterionic, as the following example should illustrate:
  • Non-ionic surfactants do not form ions in an aqueous medium.
  • acylglutamates for example sodium acylglutamate, di-TEA-palmitoylaspartate and sodium caprylic / capric glutamate,
  • acyl peptides for example palmitoyl-hydrolyzed milk protein, sodium cocoyl-hydrolyzed soy protein and sodium / potassium cocoyl-hydrolyzed collagen,
  • sarcosinates for example myristoyl sarcosin, TEA-lauroyl sarcosinate, sodium lauroyl sarcosinate and sodium cocoyl sarcosinate
  • taurates for example sodium lauroyl taurate and sodium methyl cocoyl taurate
  • carboxylic acids for example lauric acid, aluminum stearate, magnesium alkenolate and zinc undecylenate,
  • ester carboxylic acids for example calcium stearoyl lactylate, laureth-6 citrate and sodium PEG-4 lauramide carboxylate,
  • ether carboxylic acids for example sodium laureth-13 carboxylate and sodium PEG-6 cocamide carboxylate, Phosphoric acid esters and salts, such as DEA-oleth-10-phosphate and dilaureth-4-phosphate,
  • acyl isethionates e.g. Sodium / ammonium cocoyl isethionate
  • alkyl sulfonates for example sodium cocosmonoglyceride sulfate, sodium C 12-1 olefin sulfonate, sodium lauryl sulfoacetate and magnesium PEG-3 cocamide sulfate, 4.
  • sulfosuccinates for example dioctyl sodium sulfosuccinate, disodium laureth sulfosuccinate, disodium lauryl sulfyl succinate sulfosuccinate aminosulfinate sulfosuccinate aminosulfinate sulfosuccinate disodium aminosulfinate sulfate succinate disodium aminosulfinate sulfate succinate disodium aminosulfinate sulfate and
  • alkyl ether sulfate for example sodium, ammonium, magnesium, MIPA, TIPA laureth sulfate, sodium and sodium C12 - 1 3 pareth
  • alkyl sulfates for example sodium, ammonium and TEA lauryl sulfate.
  • Cationic Surfactants Cationic surfactants to be used advantageously are
  • Quaternary surfactants contain at least one N atom which is covalently bonded to 4 alkyl or aryl groups. Regardless of the pH value, this leads to a positive charge.
  • Alkyl betaine, alkyl amidopropyl betaine and alkyl amidopropyl hydroxysulfain are advantageous.
  • the cationic surfactants used in the invention can be also preferably selected from the group of quaternary ammonium compounds, in particular benzene zyltrialkylammoniumchloride or bromides, such as Benzyldimethylstea- rylammoniumchlorid, also alkyltrialkylammonium, such as for example Ce tyltrimethylammoniumchlorid or bromide, alkyldimethylhydroxyethylammonium chlorides or bromides, dialkyldimethylammonium chlorides or -bromides, alkylamidethyltrimethylam- monium ether sulfates, alkylpyridinium salts, for example lauryl or cetylpyrimidinium chloride, imidazoline derivatives and compounds with a cationic character such as amine oxides, for example alkyldimethylamine oxides or alkylaminoethyldimethylamine oxides. Cetylt methylam
  • acyl / dialkyl ethylenediamine for example sodium acyl amphoacetate, disodium acyl amphodipropionate, disodium alkyl amphodiacetate, sodium acylamphohydroxypropyl sulfonate, disodium acylamphodiacetate and sodium acylamphopropionate,
  • N-alkylamino acids for example aminopropylalkylglutamide, alkylaminopropionic acid, sodium alkylimidodipropionate and lauroamphocarboxyglycinate.
  • Non-ionic surfactants are non-ionic surfactants that can be used advantageously
  • alkanolamides such as cocamides MEA / DEA / MIPA
  • amine oxides such as cocoamidopropylamine oxide
  • esters which are formed by esterification of carboxylic acids with ethylene oxide, glycerol, sorbitan or other alcohols,
  • ethers for example ethoxylated / propoxylated alcohols, ethoxylated / propoxylated esters, ethoxylated / propoxylated glycerol esters, ethoxylated / propoxylated cholesterols, ethoxylated / propoxylated triglyceride esters, ethoxylated propoxylated lanolin, ethoxylated / propoxylated polysiloxanes, propoxylated POE ethers and alkylpolyglycosides such as lauryl polyglycosides cocoglycoside.
  • the surface-active substance can be present in the preparations according to the invention in a concentration between 1 and 95% by weight, based on the total weight of the preparations.
  • the lipid phase of the cosmetic or dermatological emulsions according to the invention can advantageously be selected from the following group of substances: mineral oils, mineral wax oils, such as triglycerides of capric or caprylic acid, and also natural oils such as e.g. Castor oil; Fats, waxes and other natural and synthetic fat bodies, preferably esters of fatty acids with alcohols of low C number, e.g.
  • the oil phase of the emulsions of the present invention is advantageously selected from the group of the esters from saturated and / or unsaturated, branched and / or unbranched alkane carboxylic acids with a chain length of 3 to 30 carbon atoms and saturated and / or unsaturated, branched and / or unbranched alcohols with a chain length of 3 to 30 C atoms, from the group of esters of aromatic carboxylic acids and saturated and / or unsaturated, branched and / or unbranched alcohols with a chain length of 3 to 30 C atoms.
  • ester oils can then advantageously be selected from the group of isopropyl myristate, isopropyl palmitate, isopropyl stearate, isopropyl oleate, n-butyl stearate, n-hexyl laurate, n-decyl oleate, isooctyl stearate, isononyistearate, isononylisononanoate, 2-ethylhexyl-2-ethylhexyl-2-ethyl-2-ethyl-2-ethyl-2-ethyl-2-ethyl-2-ethyl-2-ethyl-2-ethyl-2-ethyl-2-ethyl-2-ethyl-2-ethylhexyl-2-ethyl-2-ethyl-2-ethyl-2-ethylhexyl-2-ethyl-2-ethyl-2-
  • the oil phase can advantageously be selected from the group of branched and unbranched hydrocarbons and waxes, the silicone oils, the dialkyl ethers, the group of saturated or unsaturated, branched or unbranched alcohols, and also the fatty acid triglycerides, especially the triglycerol esters of saturated and / or unsaturated, comparable branched and / or unbranched alkane carboxylic acids with a chain length of 8 to 24, in particular 12 - 18 carbon atoms.
  • the fatty acid triglycerides can, for example, advantageously be selected from the group of synthetic, semisynthetic and natural oils, for example olive oil, sunflower oil, soybean oil, peanut oil, rapeseed oil, almond oil, palm oil, coconut oil, palm kernel oil and the like.
  • any mixtures of such oil and wax components can also be used advantageously for the purposes of the present invention. It may also be advantageous, where appropriate, to use waxes, for example cetyl palmitate, as the sole lipid component of the oil phase.
  • the oil phase is advantageously selected from the group 2-ethylhexyl isostearate, octyldodecanol, isotridecylisononanoate, isoeicosane, 2-ethylhexyl cocoate, C ⁇ 2- ⁇ 5 alkyl benzoate, caprylic capric acid re-trig lyceride, dicaprylyl ether.
  • C 12 are particularly advantageous. 5 alkyl benzoate and 2-ethylhexyl isostearate, mixtures of C 2-15 alkyl benzoate and isotridecyl isononanoate and mixtures of C 1 . 15 alkyl benzoate, 2-ethylhexyl isostearate and isotridecyl isononanoate.
  • hydrocarbons paraffin oil, squalane and squalene can be used advantageously for the purposes of the present invention.
  • the oil phase can advantageously also have a content of cyclic or linear silicone oils or consist entirely of such oils, although it is preferred to use an additional content of other oil phase components in addition to the silicone oil or the silicone oils.
  • Such silicones or silicone oils can be present as monomers, which are generally characterized by structural elements, as follows:
  • Linear silicones with a plurality of siloxyl units which can advantageously be used according to the invention are generally characterized by structural elements as follows: wherein the silicon atoms can be substituted with the same or different alkyl radicals and / or aryl radicals, which are generally represented by the radicals R 1 - R 4 (to say that the number of different radicals is not necessarily limited to up to 4), m can assume values from 2 - 200,000.
  • n assume values from 3/2 to 20.
  • broken values for n take into account that there may be odd numbers of siloxyl groups in the cycle.
  • Cyclomethicone e.g. decamethylcyclopentasiloxane
  • silicone oils can also be used advantageously for the purposes of the present invention, for example undecamethylcyclotrisiloxane, polydimethylsiloxane, poly (methylphenylsiloxane), cetyldimethicone, behenoxydimethicone.
  • silicone oils of a constitution similar to the above-mentioned compounds, the organic side chains of which are derivatized, for example polyethoxylated and / or polypropoxylated.
  • silicone oils include, for example, polysiloxane-polyalkyl-polyether copolymers such as the cetyl-dimethicone copolyol, the (cetyl-dimethicone copolyol (and) polyglyceryl-4-isostearate (and) hexyl laurate)
  • the aqueous phase of the preparations according to the invention advantageously advantageously contains alcohols, diols or polyols of low C number, and their ethers, preferably ethanol, isopropanol, propylene glycol, glycerol, ethylene glycol, ethylene glycol monoethyl or monobutyl ether, propylene glycol monomethyl, monoethyl or monobutyl ether , Diethy- glycol monomethyl or monoethyl ether and analog products, furthermore alcohols of low C number, for example Ethanol, isopropanol, 1, 2-propanediol, glycerol and in particular one or more thickeners, which one or more can advantageously be selected from the group consisting of silicon dioxide and aluminum silicates.
  • alcohols, diols or polyols of low C number, and their ethers preferably ethanol, isopropanol, propylene glycol, glycerol, ethylene glycol,
  • Preparations according to the invention which are present as emulsions particularly advantageously contain one or more hydrocolloids.
  • hydrocolloids can advantageously be selected from the group consisting of gums, polysaccharides, cellulose derivatives, layered silicates, polyacrylates and / or other polymers.
  • Preparations according to the invention which are present as hydrogels contain one or more hydrocolloids. These hydrocolloids can advantageously be selected from the aforementioned group.
  • Gums include plant or tree sap that harden in the air and form resins or extracts from aquatic plants. Gum arabic, locust bean gum, tragacanth, karaya, guar gum, pectin, gellan gum, carrageenan, agar, algine, chondrus, xanthan gum can advantageously be selected from this group for the purposes of the present invention.
  • derivatized gums such as hydroxypropyl guar (Jaguar® HP 8) is also advantageous.
  • polysaccharides and derivatives are e.g. Hyaluronic acid, chitin and chitosan, chondroitin sulfates, starch and starch derivatives.
  • cellulose derivatives are e.g. Methyl cellulose, carboxymethyl cellulose, hydroxyethyl cellulose, hydroxypropyl methyl cellulose.
  • Layered silicates contain naturally occurring and synthetic clays such as Montmorillonite, bentonite, hectorite, laponite, magnesium aluminum silicates such as Vegegum®. These can be used as such or in a modified form such as e.g. Stearylalkonium hectorite.
  • silica gels can also advantageously be used.
  • the polyacrylates include e.g. Carbopol types from Goodrich (Carbopol 980, 981, 1382, 5984, 2984, EDT 2001 or Pemulen TR2).
  • polymers e.g. Polyacrylamides (Seppigel 305), polyvinyl alcohol, PVP, PVP / VA copolymers, polyglycols.
  • Preparations according to the invention in the form of emulsions contain one or more emulsifiers.
  • emulsifiers can advantageously be selected from the group of nonionic, anionic, cationic or amphoteric emulsifiers.
  • nonionic emulsifiers are a) partial fatty acid esters and fatty acid esters of polyhydric alcohols and their ethoxylated derivatives (e.g. glyceryl monostearates, sorbitan stearates, glyceryl stearyl citrates, sucrose stearates) b) ethoxylated fatty alcohols and fatty acids c) ethoxylated fatty amides, fatty acid glycol amides, fatty acid glycol amides, fatty acid glycol amides, fatty acid glycol amides, e.g. Triton X)
  • the anionic emulsifiers include a) soaps (e.g. sodium stearate) b) fatty alcohol sulfates c) mono-, di- and trialkylphosphonic acid esters and their ethoxylates
  • the cationic emulsifiers include a) quaternary ammonium compounds with a long-chain aliphatic radical, e.g. Distearyldimonium Chloride
  • amphoteric emulsifiers include: a) alkylamininoalkane carboxylic acids b) betaines, sulfobetaines c) imidazoline derivatives
  • emulsifiers which include beeswax, wool wax, lecithin and sterols.
  • O / V emulsifiers can, for example, advantageously be selected from the group of the polyethoxylated or polypropoxylated or polyethoxylated and polypropoxylated products, for example: the fatty alcohol ethoxylates of the ethoxylated wool wax alcohols, the polyethylene glycol ethers of the general formula R-0 - (- CH 2 -CH 2 -0-) n -R ', the fatty acid ethoxylates of the general formula R-COO - (- CH 2 -CH 2 -0-) n -H, the etherified fatty acid ethoxylates of the general formula R-C00 - (- CH 2 -CH 2 -0-) n -R ', the esterified fatty acid ethoxylates of the general formula R-C00 - (- CH 2 -CH 2 -0-) n -C (0) -R', - the polyethylene glycol glycerol
  • the polyethoxylated or polypropoxylated or polyethoxylated and polypropoxylated O / W emulsifiers used are particularly advantageously selected from the group of substances with HLB values of 11-18, very particularly advantageously with HLB values of 14.5 - 15.5, provided the O / W emulsifiers have saturated residues R and R '. If the O / W emulsifiers have unsaturated radicals R and / or R ', or if isoalkyl derivatives are present, the preferred HLB value of such emulsifiers can also be lower or higher.
  • fatty alcohol ethoxylates from the group of the ethoxylated stearyl alcohols, cetyl alcohols, cetylstearyl alcohols (cetearyl alcohols).
  • cetyl alcohols cetylstearyl alcohols
  • cetearyl alcohols cetearyl alcohols
  • Polyethylene glycol (12) lauryl ether (Laureth-12), polyethylene glycol (12) isolauryl ether (Isolureth-12).
  • the sodium laureth-11 carboxylate can advantageously be used as the ethoxylated alkyl ether carboxylic acid or its salt.
  • Sodium laureth 1-4 sulfate can advantageously be used as alkyl ether sulfate.
  • Polyethylene glycol (30) cholesteryl ether can advantageously be used as the ethoxylated cholesterol derivative.
  • Polyethylene glycol (25) soyasterol has also proven itself.
  • polyethylene glycol glycerol fatty acid esters from the group polyethylene glycol (20) glyceryl laurate, polyethylene glycol (21) glyceryl laurate, polyethylene glycol (22) glyceryl laurate, polyethylene glycol (23) glyceryl laurate, polyethylene glycol (6) glyceryl caprolate caprinate, polyethylene glycol
  • polyethylene glycol (20) glyceryl isostearate polyethylene glycol (18) glyceryl oleate / cocoat.
  • sorbitan esters from the group consisting of polyethylene glycol (20) sorbitan monolaurate, polyethylene glycol (20) sorbitan monostearate, polyethylene glycol (20) sorbitan monoisostearate, polyethylene glycol (20) sorbitan monopalmitate, polyethylene glycol (20) sorbitan monooleate.
  • W / O emulsifiers that can be used are: fatty alcohols with 8 to 30 carbon atoms, monoglycerol esters of saturated and / or unsaturated, branched and / or unbranched alkane carboxylic acids with a chain length of 8 to 24, in particular 12 to 18 carbon atoms, diglycerol esters saturated and / or unsaturated, branched and / or unbranched alkane carboxylic acids with a chain length of 8 to 24, in particular 12 to 18 carbon atoms, monoglycerol ethers saturated and / or unsaturated, branched and / or unbranched alcohols with a chain length of 8 to 24, in particular 12 to 18 C atoms, diglycerine ethers of saturated and / or unsaturated, branched and / or unbranched alcohols with a chain length of 8 to 24, in particular 12-18 C atoms, propylene glycol esters of saturated and / or unsaturated, branched and / or unbranche
  • W / O emulsifiers are glyceryl stearate Glycerylmonoiso-, glyceryl monomyristate, glyceryl, diglyceryl monostearate, Diglycerylmono- isostearate, propylene glycol caprylate, propylene glycol monoisostearate, propylene glycol, Propylengiycolmonolaurat, sorbitan, sorbitan, sorbitan monocaprylate, Sorbitanmonoisooleat, sucrose, cetyl alcohol, stearyl alcohol, Arachidyl alcohol, behenyl alcohol, isobehenyl alcohol, selachyl alcohol, chimyl alcohol, polyethylene glycol (2) stearyl ether (Steareth-2), glyceryl monolaurate, glyceryl monocaprinate, glyceryl monocaprylate.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Birds (AREA)
  • Microbiology (AREA)
  • Botany (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • Medical Informatics (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Emergency Medicine (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Cosmetics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'invention concerne des associations de substance active comprenant : (a) un ou plusieurs dérivés de 2,3-dibenzylbutyrolactone, et ; (b) le composé licochalcone-A ou un extrait aqueux de Radix Glycyrrhizae inflatae qui contient le composé licochalcone-A.
EP04819609A 2003-12-03 2004-11-22 Association de 2,3-dibenzylbutyrolactone et de licochalcone-a Withdrawn EP1696903A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10357451A DE10357451A1 (de) 2003-12-03 2003-12-03 Wirkstoffkombinationen aus 2,3-Dibenzylbutyrolactonen und Licochalcon A oder einem wässrigen Extrakt aus Radix Glycyrrhizae inflatae, enthaltend Licochalcon A
PCT/EP2004/013254 WO2005053680A1 (fr) 2003-12-03 2004-11-22 Association de 2,3-dibenzylbutyrolactone et de licochalcone-a

Publications (1)

Publication Number Publication Date
EP1696903A1 true EP1696903A1 (fr) 2006-09-06

Family

ID=34638524

Family Applications (1)

Application Number Title Priority Date Filing Date
EP04819609A Withdrawn EP1696903A1 (fr) 2003-12-03 2004-11-22 Association de 2,3-dibenzylbutyrolactone et de licochalcone-a

Country Status (5)

Country Link
US (1) US20070110704A1 (fr)
EP (1) EP1696903A1 (fr)
JP (1) JP2007513104A (fr)
DE (1) DE10357451A1 (fr)
WO (1) WO2005053680A1 (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10224387A1 (de) 2002-06-01 2003-12-11 Beiersdorf Ag Kosmetische oder dermatologische Zubereitungen mit einem aufbereiteten Extrakt aus Radix Glycyrrhizae inflatae
DE10356164A1 (de) * 2003-12-02 2005-08-04 Beiersdorf Ag Wirkstoffkombinationen aus Licochalcon A oder einem Extrakt aus Radix Clycyrrhizae inflatae, enthaltend Licochalcon A, Phenoxyethanol und gewünschtenfalls Glycerin
DE102006010589A1 (de) * 2006-03-06 2007-09-13 Beiersdorf Ag Kosmetische oder dermatologische Emulsionen enthaltend Licocalchon A oder einen Licocalchon A enthaltenden Extraxt aus Radix Glycyrrhizae inflatae
KR100855457B1 (ko) * 2007-02-28 2008-09-01 주식회사 코리아나화장품 악틴, 악티게닌 또는 그의 혼합물을 유효성분으로 함유하는피부미백용 화장료 조성물
KR100901661B1 (ko) 2007-07-13 2009-06-08 바이오스펙트럼 주식회사 악티게닌을 유효성분으로 포함하는 피부주름 개선용 조성물
DE102007062691A1 (de) * 2007-12-21 2009-06-25 Beiersdorf Ag Wirkstoffkombinationen aus Anisfruchtextrakt und einem oder mehreren 2,3-Dibenzylbutyrolactonen
DE202008018656U1 (de) 2008-09-16 2017-11-07 Beiersdorf Ag UV-Filter haltige O/W-Wirkstoffemulsion
DE102008048328A1 (de) 2008-09-16 2010-04-15 Beiersdorf Ag UV-Filter haltige O/W-Wirkstoffemulsion
ES2735991T3 (es) * 2009-09-29 2019-12-23 Shiseido Co Ltd Composición antioxidante
US9675538B2 (en) 2012-03-30 2017-06-13 Rohto Pharmaceutical Co., Ltd. Anti-aging agent containing arctigenin derivative
KR102166555B1 (ko) * 2013-06-28 2020-10-16 스미또모 세이까 가부시키가이샤 친수성 증점제 및 화장료 조성물
CN104083541A (zh) * 2014-06-30 2014-10-08 丁小双 一种用于治疗疔疮的中药及其制备方法
ITUB20150330A1 (it) * 2015-02-05 2016-08-05 Novamont Spa Processo per il frazionamento di semi di piante oleaginose.
DE102018201598A1 (de) * 2018-02-02 2019-08-08 Beiersdorf Ag Stabile Wundheilsalbe
CN113440501A (zh) * 2021-06-22 2021-09-28 西安市红会医院 甘草查尔酮a在制备抗过敏药物中的应用

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US186295A (en) * 1877-01-16 Improvement in machines for washing hat-bodies
US22665A (en) * 1859-01-18 Gomery
US136139A (en) * 1873-02-25 Improvement in blacksmiths hammers
US158259A (en) * 1874-12-29 Improvement
US191266A (en) * 1877-05-29 Improvement in glove-fasteners
US37042A (en) * 1862-12-02 Improvement in heaters and ventilators for tents
US509875A (en) * 1893-12-05 Scraper or shovel
US93633A (en) * 1869-08-10 Improvement in spindle and bobbin tubes for spinning-machines
US158350A (en) * 1875-01-05 Improvement in buckles
US201967A (en) * 1878-04-02 Improvement in atomizers
US4144325A (en) * 1976-11-10 1979-03-13 Voyt Walter F Method of and composition for preventing sunburn while affording tanning
US4248861A (en) * 1979-02-21 1981-02-03 Schutt Steven R Skin treatment methods
DE3314742A1 (de) * 1983-04-23 1984-10-25 Degussa Ag, 6000 Frankfurt An der oberflaeche modifizierte natuerliche oxidische oder silikatische fuellstoffe, ein verfahren zur herstellung und deren verwendung
IL109012A (en) * 1994-03-17 1998-09-24 Fischer Pharma Ltd Skin whitening composition comprising glycyrrhyza glabra and hydroxy acids
EP0998939A1 (fr) * 1998-09-09 2000-05-10 The School Of Pharmacy, University Of London Extraits de plantes à base de chalcone utilisables en thérapie
US6214352B1 (en) * 2000-01-06 2001-04-10 Matsukawa Kagaku Co., Ltd. Tyrosinase inhibiting agent
ATE304367T1 (de) * 2000-06-13 2005-09-15 Univ Rutgers Anti-karzinogene aktivität von aus der lakritzenwurzel isolierten hydroxylierten chalcon-verbindungen
KR20020046615A (ko) * 2000-12-15 2002-06-21 유상옥,송운한 우방자추출물을 함유하는 미백제
JP4577868B2 (ja) * 2001-10-23 2010-11-10 株式会社資生堂 マトリックスメタロプロテアーゼ活性阻害剤
DE10207919A1 (de) * 2002-02-23 2003-09-18 Cognis Deutschland Gmbh Anti-Ageingmittel
DE10223486A1 (de) * 2002-05-27 2003-12-11 Beiersdorf Ag Kosmetische und/oder dermatologische Zubereitung mit 2,3-Dibenzylbutyrolactonen
DE10224387A1 (de) * 2002-06-01 2003-12-11 Beiersdorf Ag Kosmetische oder dermatologische Zubereitungen mit einem aufbereiteten Extrakt aus Radix Glycyrrhizae inflatae
FI20021184A (fi) * 2002-06-19 2003-12-20 Hormos Nutraceutical Oy Ltd Lignaanivalmisteita

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2005053680A1 *

Also Published As

Publication number Publication date
WO2005053680A1 (fr) 2005-06-16
DE10357451A1 (de) 2005-07-07
US20070110704A1 (en) 2007-05-17
JP2007513104A (ja) 2007-05-24

Similar Documents

Publication Publication Date Title
DE10223486A1 (de) Kosmetische und/oder dermatologische Zubereitung mit 2,3-Dibenzylbutyrolactonen
EP1537855A1 (fr) Composition cosmétique comprenant licochalcone A ou un extrait de Glycyrrhiza inflatae comprenant licochalcone A et un épaisissant
EP3406243B1 (fr) Combinaisons de substances actives de la licochalcone a ou d'un extrait de radix glycyrrhizae inflatae contenant de la licochalcone a, du phénoxyéthanol et éventuellement de la glycérine
EP1696903A1 (fr) Association de 2,3-dibenzylbutyrolactone et de licochalcone-a
WO2003007908A2 (fr) Preparations cosmetiques ou dermatologiques ayant une action de refroidissement de longue duree
EP1401389A2 (fr) Utilisation de carnitine et/ou d'une ou de plusieurs acyl-carnitines pour realiser des preparations cosmetiques ou dermatologiques destinees a accroitre la biosynthese de ceramide
DE10356187A1 (de) Wirkstoffkombinationen aus Phytosterolen und/oder Cholesterin und Licochalcon A oder einem wäßrigen Extrakt aus Radix Glycyrrhizae inflatae, enthaltend Licochalcon A
DE10129504A1 (de) Verwendung von Carnitin und/oder einem oder mehreren Acyl-Carnitinen zur Herstellung von kosmetischen oder dermatologischen Zubereitungen zur Behandlung und/oder Prophylaxe von Pigmentierungsstörungen
EP1367987A2 (fr) Utilisation de combinaisons d'agents actifs composees d'acide alpha-liponique et de substances dermatologiquement acceptables presentant une absorption de lumiere dans la gamme des uv-a et uv-b, pour la fabrication de preparations cosmetiques et dermatologiques
WO2002094211A1 (fr) Compositions cosmetiques ou dermatologiques contenant une ou plusieurs cetohexoses
EP1449514A1 (fr) Préparations pour le soin de la peau contenant des rétinoides, des ubiquinones, et de la biotine ou de la carnitine
EP1676571A1 (fr) Composition comprenant au moins un isoflavone et du carnitine et/ ou au moins un acyl-carnitine
DE10111048A1 (de) Verwendung von alpha-Liponsäure zur Herstellung kosmetischer oder dermatologischer Zubereitungen zur Regeneration beanspruchter Haut, insbesondere der gealterten Haut
WO2002069911A2 (fr) Combinaisons de principes actifs, reunissant de l'acide $g(a)-lipoique et des bioquinones
DE10121090A1 (de) Wirkstoffkombinationen aus Tetrahydrocurcuminoiden und Sericosid und/oder Pflanzenextrakten
DE10217256A1 (de) Kosmetische und dermatologische Zubereitungen mit einem Gehalt an einem oder mehreren Phytochelatinen
DE10207274A1 (de) Wirkstoffkombinationen aus Tetrahydrocurcuminoiden und alpha-Liponsäure
DE102005019549A1 (de) Kosmetische oder dermatologische Zubereitungen mit einem Gehalt an Diaminobenzimidazol
WO2003007909A2 (fr) Preparations cosmetiques ou medicales a effet rafraichissant durable
DE10241889A1 (de) Kosmetische oder dermatologische Zubereitungen mit einem Gehalt an Chinolinsäure und/oder ihren Derivaten
DE10146802A1 (de) Vitaminhaltige Hautpflegeprodukte
DE102004026238A1 (de) Kosmetische Zubereitungen mit einem Gehalt an Benfotiamin
DE10121089A1 (de) Wirkstoffkombinationen aus Tetrahydrocurcuminoiden und Substanzen, die verhindern, dass die NO-Synthase des warmblütigen Organismus seine Wirkung entfaltet
DE10132341A1 (de) Kosmetische oder dermatologische Zubereitungen mit einem Gehalt an Apoferritin
DE10139851A1 (de) Hautpflegeprodukte mit einer Kombination aus Biotin, Ubichinonen und Cyclodextrinen

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20060703

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LU MC NL PL PT RO SE SI SK TR

DAX Request for extension of the european patent (deleted)
17Q First examination report despatched

Effective date: 20100927

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20120703